{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1380855569831707650.json","@type":"Researcher","foaf:Person":[{"foaf:name":[{"@value":"Michael E Franks"}],"foaf:familyName":[{"@value":"Franks"}],"foaf:givenName":[{"@value":"Michael E"}]}],"product":[{"@id":"https://cir.nii.ac.jp/crid/1360855569831707648","@type":"Article","productIdentifier":[{"@type":"DOI","@value":"10.1016/s0140-6736(04)16308-3"},{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0140673604163083?httpAccept=text/xml"},{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0140673604163083?httpAccept=text/plain"}],"notation":[{"@value":"Thalidomide"}],"relation":[{"type":"creator"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1016/s0140-6736(04)16308-3_G9eLSZohPB7cQg9m4J33XggLggo"}]}